Keywords: Bayer, Ortho-McNeil, Johnson & Johnson, Xarelto, VTE, Decision Resources

Bayer/Ortho-McNeil’s VTE drug Xarelto will earn peak-year sales of $500 million to $1 billion

Article | 17 May 2011

Print This

Following its expected launch in the USA in 2012 for venous thromboembolism (VTE) prophylaxis in medically ill patients, the overall uptake ...

Enjoying this article? To continue reading you need to login or subscribe.

Subscribe now
for unlimited access to all articles

Subscriptions are £60 per month, pay as you go.
Find out more details.

Already a subscriber? Click here to log in